Internal Deadline: Friday, March 4, 2022, 5pm PT
LOI: 30 days prior to the application due date.
External Deadline: June 3, 2022
Award Type: Cooperative Agreement
Estimated Number of Awards: 4-5
Anticipated Award Amount: $7.674 million
Who May Serve as PI: Note that the multiple PD(s)/PI(s) option may be used only for the Overall Program. Projects are limited to a single project lead per project and a single core lead per core within the multi-component application.
An investigator can serve as a PD/PI on only one AADCRC award or application. This includes all PD(s)/PI(s) of a multiple-PD/PI application.
Note that the current FOA will not allow foreign clinical trial sites. However, foreign components that will be allowed include mechanistic projects, observational studies, specialized assay, etc.
Process for Limited Submissions
PIs must submit their application as a Limited Submission through the Office of Research Application Portal: https://orif.usc.edu/oor-portal/.
Materials to submit include:
- (1) Single Page Proposal Summary (0.5” margins; single-spaced; font type: Arial, Helvetica, or Georgia typeface; font size: 11 pt). Page limit includes references and illustrations. Pages that exceed the 1-page limit will be excluded from review.
- (2) CV – (5 pages maximum)
Note: The portal requires information about the PIs and Co-PIs in addition to department and contact information, including the 10-digit USC ID#, Gender, and Ethnicity. Please have this material prepared before beginning this application.
This Funding Opportunity Announcement (FOA) invites applications from single institutions or consortia of institutions to participate in the Asthma and Allergic Diseases Cooperative Research Centers (AADCRC) program. The program will support centers that integrate clinical and translational research to conduct studies on the mechanisms underlying the onset and progression of diseases of interest including asthma, rhinitis (allergic and non-allergic), chronic rhinosinusitis, atopic dermatitis, food allergy, and drug allergy. The overarching goal of the program is to improve the understanding of the pathogenesis of these conditions and to provide a rational foundation for new, effective treatments and prevention strategies.
The objective of this FOA is to support multidisciplinary research on the following conditions of interest: immunopathophysiology of asthma, rhinitis (allergic and non-allergic), chronic rhinosinusitis, atopic dermatitis, food allergy, and drug allergy. The overall goal of the AADCRC program is to improve the understanding of the pathogenesis of these conditions and to provide a rational foundation for new, effective treatments and prevention strategies.
NIAID programmatic priorities for this FOA are:
- The role of innate and adaptive immune functions in the development and pathogenesis of asthma and allergic diseases with a focus on severe asthma, chronic rhinosinusitis, atopic dermatitis, and drug allergy;
- The impact of the microbiome and of pollution on immune responses as they pertain to the development, prevention and management of asthma, allergic rhinitis, food allergy and atopic dermatitis;
- The interaction between infections and atopy and the role of immune responses to infections in the development and exacerbations of asthma, allergic rhinitis, chronic rhinosinusitis, and atopic dermatitis;
- Understanding the mechanisms of allergen immunotherapy-induced clinical desensitization and tolerance for the treatment and prevention of asthma, allergic rhinitis and food allergy and improving the efficacy, safety and ease of use of this therapeutic modality;
- Identifying genetic variations and epigenetic alterations affecting host immune responses to aeroallergens, food allergens and drug allergens and patient responses to therapeutic interventions in asthma, allergic rhinitis, chronic rhinosinusitis, atopic dermatitis and drug allergy;
- Clinical, immunologic and physiologic phenotyping and endotyping of drug allergy, chronic rhinosinusitis and non-allergic rhinitis syndromes that provide mechanistic insights for disease etiology or management.
Visit our Institutionally Limited Submission webpage for more updates and other announcements.